gdc
FDA Approvals, News & UpdatesGynecologic CancersNewsworthyOvarian Cancer

Lynparza Approved as Maintenance Treatment for Ovarian Cancer

In August 2017, the FDA approved Lynparza tablets for the maintenance treatment of adults with recurrent epithelial ovarian, fallopian tube, or peritoneal cancer who had a response to platinum-based chemotherapy.
December 2017 Vol 3 No 6

Also on August 17, 2017, the FDA approved Lynparza (olaparib; from AstraZeneca) tablets for the maintenance treatment of adults with recurrent epithelial ovarian, fallopian tube, or peritoneal cancer who had a complete or partial response to platinum-based chemotherapy.

On the same day, the FDA also approved a tablet form of Lynparza for patients with deleterious or suspected deleterious germline BRCA mutation–positive advanced ovarian cancer who have received 3 or more previous chemotherapies.

The most common side effects with Lynparza include anemia, nausea, fatigue, vomiting, nasopharyngitis, diarrhea, constipation, stomatitis, headache, dysgeusia, dyspepsia, decreased appetite, arthralgia, or myalgia.

Recommended For You
COVID-19 (Coronavirus)From Your NavigatorNewsworthyWeb Exclusives
Coronavirus FAQs for People with Cancer: Interview with Lillie D. Shockney, RN, BS, MAS, HON-ONN-CG
By Yvette Florio Lane
COVID-19, the respiratory infection caused by the new coronavirus, is making headlines around the world. Find out what you need to know about this global disease outbreak and how to protect yourself.
Ovarian Cancer
Zejula Approved for HRD-Positive Advanced Ovarian Cancer
Late last year, the PARP inhibitor Zejula was approved by the FDA for patients with HRD mutation associated with advanced ovarian, fallopian tube, or primary peritoneal cancer, offering a new treatment option for women with these types of cancer.
Ovarian Cancer
Ovarian Cancer Patient Advocacy Organizations
There are a number of excellent organizations providing resources and support to you as a patient with ovarian cancer or a caregiver.
Ovarian Cancer
Ovarian Cancer: Progress Occurs, but Far Too Slowly
By Annette Bennington McElhiney, PhD
As a retired college professor, Dr. McElhiney uses her personal experience with ovarian cancer to advocate for other patients, urging faster development of new treatment options.
Last modified: June 20, 2019

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country